- 21 November 2023Portfolio NewsDementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck
- 21 November 2023Portfolio NewsMerck to Acquire Caraway Therapeutics, Inc.
- 14 November 2023Portfolio NewsTransposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases
- 14 November 2023Portfolio NewsEyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
- 13 November 2023Portfolio NewsCerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease
- 12 November 2023Portfolio NewsImbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina
- 8 November 2023SV NewsSV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 7 November 2023Portfolio NewsImbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
- 6 November 2023Portfolio NewsAviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
- 2 November 2023Portfolio NewsPerfuze Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System
- 1 November 2023Portfolio NewsVibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia
- 1 November 2023Portfolio NewsSitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases